|12/06/13||Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER™ Stent System |
|NATICK, Mass. and PARSIPPANY, N.J., Dec. 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System. Under the terms of the agreement, The Medicines Company's acute cardiovascular care sales force will collaborate with the Boston Scientific Interventional Cardiology sales force to provide promotional su... |
|12/04/13||The Medicines Company Acquires Rempex Pharmaceuticals|
|Novel Portfolio of Gram-Negative Antibiotics in Development Added to The Medicines Company's Infectious Disease Hospital Care Franchise
PARSIPPANY, NJ and SAN DIEGO, CA -- (Marketwired) -- 12/04/13 --
The Medicines Company (NASDAQ: MDCO) today announced that it has acquired Rempex Pharmaceuticals, Inc., a company with multiple potential new therapies focused on multi-drug resistant gram-negative bacteria.
Clive Meanwell, MD, PhD, Chairman and Chief Executive Officer of The Medicines Company... |
|11/27/13||The Medicines Company to Participate in Upcoming Investor Conference Webcasts|
|PARSIPPANY, NJ -- (Marketwired) -- 11/27/13 --
The Medicines Company (NASDAQ: MDCO) is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference on December 4th at 12:30 PM Eastern Time. MDCO is also scheduled to present at the Oppenheimer 24th Annual Conference, December 11th at 1:00 PM Eastern Time.
Both sessions will be webcast with a link available at The Medicines Company's website http://www.themedicinescompany.com.
About The Medicines Company
The Medicine... |
|11/21/13||European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Fibrocaps Hemostatic Agent|
|PARSIPPANY, NJ -- (Marketwired) -- 11/21/13 --
The Medicines Company (NASDAQ: MDCO) today announced that the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational hemostatic agent Fibrocaps (human plasma-derived fibrinogen and thrombin). Fibrocaps was studied in the 719-patient Phase III FINISH-3 clinical trial as an adjunct to hemostasis in patients undergoing surgical procedures when control of mild or moderate bleeding by... |